Financial support will enable company to pursue the identification and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance.
Menu
Financial support will enable company to pursue the identification and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance.